Until recently, the development of new human adjuvants was held back by a poor
understanding of their mechanisms of action. The field was revolutionized by the discovery …

Background Additional interventions are needed to reduce the morbidity and mortality
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …

The induction of protective humoral immune responses against sporozoite surface proteins
of the human parasite Plasmodium falciparum (Pf) is a prime goal in the development of a …

Elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor in the
development of atherosclerotic cardiovascular disease (ASCVD). Inhibitors of proprotein …

Background Human monoclonal antibodies might offer an important new approach to
reduce malaria morbidity and mortality. In the first two parts of a three-part clinical trial, the …

Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths
annually. EBV is also the etiological agent of infectious mononucleosis and is linked to …

Repeat antigens, such as the Plasmodium falciparum circumsporozoite protein (PfCSP), use
both sequence degeneracy and structural diversity to evade the immune response. A few …

Abstract The Circumsporozoite Protein (CSP) of Plasmodium falciparum contains an N-
terminal region, a conserved Region I (RI), a junctional region, 25–42 copies of major …

Human papilloma virus type 16 (HPV16) is the most prevalent etiologic agent associated
with cervical cancer, and its early proteins E5, E6 and E7 play important roles in cervical …

Malaria is a complex disease caused by parasites of the genus Plasmodium and is the
leading cause of morbidity and mortality worldwide. The most severe form of malaria …